TDP-43 Transgenic Mouse Models
Target the pathological hallmark of frontotemporal dementia (FTD) and almost all Amyotrophic lateral sclerosis patients with our TDP-43 proteinopathy models
Mutations in the gene encoding TAR DNA-binding protein 43 (TDP-43) are associated with familial ALS, and virtually all sporadic ALS cases have TDP-43 inclusions. TDP-43 transgenic models overexpress the mutant form of human TDP-43, leading to motoneuron degeneration and paralysis.
Take advantage of InnoSer’s preclinical research expertise, flexibility, and collaborative approach for your research. We support our clients in identifying new drugs or applications, characterizing their pharmacological properties, and conducting safety and efficacy testing with state-of-the-art readout capabilities and histopathological analysis.
TDP-43 Transgenic Mouse Model key characteristics:
- Available with and without disease-associated mutations.
- Abnormal accumulation of TDP-43.
- Motor deficits.
Find the right model for you.
Compare our model capabilities and discover which of our neurology platforms suits your research needs
Test the efficacy of your treatments in the following battery of behavioural tests:
- Spontaneous Behavior (PhenoTyper™)
- Neurological scoring
- Balance beam
- Grip strength
- Wire hanging
- Nest building
- MSD (e.g. cytokines in brain/spinal cord, plasma NF-L)
- Immunohistochemistry (TDP-43 accumulation, neuroinflammation, neurodegeneration)
- Immunofluorescence and FISH
Related ALS Disease model options
Neurology Platform Overview
TDP-43 Seeding Models
Transgenic SOD1 models
InnoSer offers unique behavioural research services with several different transgenic SOD1 mouse models.
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
Need more information?
If you have any questions about how we can help accelerate your research,
then let us know